2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Sweden Leader Award
2022 - Research.com Neuroscience in Sweden Leader Award
2017 - Nordic Medical Prize, SalusAnsvar/Ulf Nilsonnes Foundation for Medical Research
His primary scientific interests are in Alzheimer's disease, Internal medicine, Pathology, Cerebrospinal fluid and Dementia. His study focuses on the intersection of Alzheimer's disease and fields such as Central nervous system disease with connections in the field of Cognitive disorder. In his research, Cohort study is intimately related to Oncology, which falls under the overarching field of Internal medicine.
His Cerebrospinal fluid research includes elements of Csf biomarkers, Immunology, Disease, Amyloid and Traumatic brain injury. His research in Dementia intersects with topics in Cognition, Neurology and Neuroimaging. The study incorporates disciplines such as Immunoassay, Neuropathology and Neurodegeneration in addition to Biomarker.
Kaj Blennow mainly investigates Internal medicine, Cerebrospinal fluid, Disease, Pathology and Biomarker. His work deals with themes such as Endocrinology, Neurology and Oncology, which intersect with Internal medicine. Kaj Blennow has included themes like Gastroenterology, Neurodegeneration, Immunology and Amyloid in his Cerebrospinal fluid study.
The various areas that Kaj Blennow examines in his Disease study include Neuroimaging, Neuroscience and Clinical trial, Bioinformatics. His Dementia research is multidisciplinary, incorporating elements of Cognition and Cohort. The concepts of his Alzheimer's disease study are interwoven with issues in Apolipoprotein E and Central nervous system disease, Degenerative disease.
His scientific interests lie mostly in Internal medicine, Cerebrospinal fluid, Disease, Biomarker and Dementia. He works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Neuroimaging. His Cerebrospinal fluid study is concerned with the larger field of Pathology.
His biological study spans a wide range of topics, including Clinical trial, Bioinformatics and Cognition, Neuroscience. His Biomarker research is multidisciplinary, relying on both Positron emission tomography, Prospective cohort study, Area under the curve and Glial fibrillary acidic protein. His Dementia study integrates concerns from other disciplines, such as Alzheimer's disease, Apolipoprotein E and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.
B. Winblad;K. Palmer;Miia Kivipelto;V. Jelic.
Journal of Internal Medicine (2004)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack;David A. Bennett;Kaj Blennow;Maria C. Carrillo.
Alzheimers & Dementia (2018)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Oskar Hansson;Oskar Hansson;Henrik Zetterberg;Peder Buchhave;Peder Buchhave;Elisabet Londos;Elisabet Londos.
Lancet Neurology (2006)
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Leslie M. Shaw;Hugo Vanderstichele;Malgorzata Knapik-Czajka;Christopher M. Clark.
Annals of Neurology (2009)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
Kaj Blennow;Harald Hampel;Michael Weiner;Henrik Zetterberg.
Nature Reviews Neurology (2010)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway;Reisa Sperling;Nick C. Fox;Kaj Blennow.
The New England Journal of Medicine (2014)
CSF markers for incipient Alzheimer's disease
Kaj Blennow;Harald Hampel.
Lancet Neurology (2003)
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson;Henrik Zetterberg;Oskar Hansson;Niels Andreasen.
JAMA (2009)
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Sandip Ray;Markus Britschgi;Charles Herbert;Yoshiko Takeda-Uchimura.
Nature Medicine (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Gothenburg
Lund University
University of Gothenburg
Lund University
University of Gothenburg
Lund University
Université Paris Cité
Maastricht University
Karolinska University Hospital
University of Gothenburg
Carnegie Mellon University
Stanford University
University of Bristol
University of Queensland
Cornell University
Oklahoma Medical Research Foundation
University of Tübingen
Wuhan University
INRAE : Institut national de recherche pour l'agriculture, l'alimentation et l'environnement
Chinese Academy of Sciences
University of Gothenburg
University Medical Center Groningen
University of California, San Diego
University of Southampton
Imperial College London
University of Tokyo